ApoB/ApoA-I ratio is associated with increased risk of bioprosthetic valve degeneration

DC FieldValueLanguage
dc.contributor.authorMahjoub, Haïfa-
dc.contributor.authorMathieu, Patrick-
dc.contributor.authorSénéchal, Mario-
dc.contributor.authorLarose, Éric-
dc.contributor.authorDumesnil, Jean G.-
dc.contributor.authorDesprés, Jean-Pierre-
dc.contributor.authorPibarot, Philippe-
dc.date.accessioned2016-06-08T13:27:35Z-
dc.date.available10000-01-01-
dc.date.issued2013-02-11-
dc.identifier.issn0735-1097fr_CA
dc.identifier.urihttp://hdl.handle.net/20.500.11794/3789-
dc.description.abstractObjectives : This study sought to identify the clinical and metabolic determinants of bioprosthetic valve degeneration. Background : Structural valve degeneration (SVD) is the major cause of bioprosthetic valve failure. Recent retrospective studies have reported an association between atherosclerotic risk factors and development of SVD. Methods : A total of 203 consecutive patients with aortic bioprosthetic valves were recruited. Doppler echocardiography and multidetector computed tomography (CT) examinations were performed for assessment of bioprosthesis calcification and abdominal adiposity. A cardiometabolic risk profile was also obtained. SVD was defined as an increase in mean transprosthetic gradient of =10 mm Hg and/or a worsening of transprosthetic regurgitation =1/3 class between 1-year post-operative echo and last follow-up echo (mean follow-up time was 8 ± 3 years). Results : Forty-two patients (20%) were identified as developing SVD. Patients with SVD had significantly higher plasma total-cholesterol (4.6 ± 1.1 mmol/l vs. 4.1 ± 0.9 mmol/l, p = 0.05), low-density lipoprotein-cholesterol (2.5 ± 1.0 mmol/l vs. 2.2 ± 0.7 mmol/l, p = 0.02), and apolipoprotein B (ApoB) levels (0.71 ± 0.22 g/l vs. 0.64 ± 0.17 g/l, p = 0.02) and higher ApoB/ApoA-I ratios (0.48 ± 0.17 vs. 0.41 ± 0.11, p = 0.004) than those with no SVD. Multivariate analysis revealed that increased ApoB/ApoA-I ratio (odds ratio [OR]: 1.41, 95% confidence interval [CI]: 1.10 to 1.82 per 0.1 increment; p = 0.007) and the use of bisphosphonates (OR: 3.57, 95% CI: 1.14 to 10.80 p = 0.02) were the strongest independent predictors of SVD. Conclusions : This is the first study to report a strong association between increased ApoB/ApoA-I ratio and the risk of developing SVD among patients with aortic bioprosthetic valves. Further studies are needed to determine if an elevated ApoB/ApoA-I ratio, which reflects the balance of proatherogenic and antiatherogenic lipoproteins, is a risk marker or a risk factor for SVD.fr_CA
dc.languageengfr_CA
dc.publisherAmerican College of Cardiologyfr_CA
dc.subjectApoB/ApoA-I ratiofr_CA
dc.subjectDoppler echocardiographyfr_CA
dc.subjectHeart valve prosthesisfr_CA
dc.titleApoB/ApoA-I ratio is associated with increased risk of bioprosthetic valve degenerationfr_CA
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherche-
dcterms.bibliographicCitationJournal of the American College of Cardiology, Vol. 61 (7), 752–761 (2013)fr_CA
dc.audienceProfesseurs (Enseignement supérieur)fr_CA
dc.audienceÉtudiantsfr_CA
dc.audienceDoctorantsfr_CA
dc.audienceMédecinsfr_CA
dc.identifier.doi10.1016/j.jacc.2012.11.033fr_CA
dc.identifier.pubmed23410546fr_CA
dc.subject.rvmApolipoprotéine A1fr_CA
dc.subject.rvmApolipoprotéine Bfr_CA
dc.subject.rvmProthèses valvulaires cardiaquesfr_CA
dc.subject.rvmÉchocardiographie Dopplerfr_CA
rioxxterms.versionVersion of Recordfr_CA
rioxxterms.version_of_recordhttps://doi.org/10.1016/j.jacc.2012.11.033fr_CA
bul.rights.periodeEmbargoInfinifr_CA
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
Description SizeFormat 
Mahjoub2013-13682.pdf
441.25 kBAdobe PDF    Request a copy
All documents in CorpusUL are protected by Copyright Act of Canada.